Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen

Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen

US Patent 12384847 · Granted Aug 12, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Human PD-L2 antibodies and methods of use therefor2025
TGF-beta superfamily type I and type II receptor heteromultimers and uses thereo2025
Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of u2025
Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of u2025
Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of u2025
Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of u2025
Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of u2025
Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of u2025
Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of u2025
Proteins binding NKG2D, CD16 and a tumor-associated antigen2025
Proteins binding NKG2D, CD16 and a tumor-associated antigen2025
Proteins binding NKG2D, CD16 and a tumor-associated antigen2025